Effects of risperidone on glutamate receptor subtypes in developing rat brain

European Neuropsychopharmacology

Volumn 19, Issue 2, 2009, Pages 77-84

  Choi, Yong Kee ^a   Gardner, Matthew P ^a   Tarazi, Frank I ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Autoradiography; Caudate putamen; Childhood onset schizophrenia; Frontal cortex; Glutamate receptors; Risperidone

Indexed keywords

AMPA RECEPTOR; GLUTAMATE RECEPTOR; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECEPTOR SUBTYPE; RISPERIDONE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; CAUDATE NUCLEUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG RECEPTOR BINDING; FOREBRAIN; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

AGING; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BRAIN; BRAIN CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE;

EID: 57749175518     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.08.010     Document Type: Article

References (54)

1. Aghajanian G.K., and Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Rev. 31 (2000) 302-312
2. Ariano M.A., Larson E.R., Noblett K.L., Sibley D.R., and Levine M.S. Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits. Synapse 26 (1997) 400-414
3. Armenteros J.L., Whitaker A.H., Welikson M., Stedge D.J., and Gorman J. Risperidone in adolescents with schizophrenia: an open pilot study. J. Am. Acad. Child Adolesc. Psych. 36 (1997) 694-700
4. Baldessarini R.J., and Tarazi F.I. Pharmacotherapy of psychosis and mania. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics (2005), McGraw-Hill, New York 461-500
5. Barnard L., Young A.H., Pearson J., Geddes J., and O'Brien G. A systematic review of the use of atypical antipsychotics in autism. J. Psychopharmacol. 16 (2002) 93-101
6. Boegman R.J., and Vincent S.R. Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse 22 (1996) 70-77
7. Bruggeman R., van der Linden C., Buitelaar J.K., Gericke G.S., Hawkridge S.M., and Temlett J.A. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J. Clin. Psychiatry 62 (2001) 50-56
8. 2+/calmodulin-dependent kinase II in prefrontal cortical pyramidal neurons. J. Biol. Chem. 277 (2002) 36553-36562
9. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Ann. Rev. Pharmacol. Toxicol. 41 (2001) 237-260
10. Carta M., Olivera D.S., Dettmer T.S., and Valenzuela C.F. Ethanol withdrawal upregulates kainate receptors in cultured rat hippocampal neurons. Neurosci. Lett. 327 (2002) 128-132
11. Cepeda C., Buchwald N.A., and Levine M.S. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 9576-9580
12. Erickson C.A., Stigler K.A., Posey D.J., and McDougle C.J. Risperidone in pervasive developmental disorders. Expert Rev. Neurother. 5 (2005) 713-719
13. Fedorowicz V.J., and Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review. J. Psychopharmacol. 19 (2005) 533-550
14. Findling R.L., and McNamara N.K. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J. Clin. Psychiatry 65 Suppl 6 (2004) 30-44
15. 3H]kainate binding in hippocampus 24 hours after PCP. Neurosci. Lett. 174 (1994) 149-153
16. Gao X.M., Sakai K., Roberts R.C., Conley R.R., Dean B., and Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-d-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry 157 (2000) 1141-1149
17. 3H]MK801-binding sites in the rat brain: a side-preference action in cortical areas. Brain Res 762 (1997) 216-218
18. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158 (2001) 1367-1377
19. Goff D.C., Leahy L., Berman I., Posever T., Herz L., Leon A.C., Johnson S.A., and Lynch G. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J. Clin. Psychopharmacol. 21 (2001) 484-487
20. Goff D.C., Lamberti J.S., Leon A.C., Green M.F., Miller A.L., Patel J., Manschreck T., Freudenreich O., and Johnson S.A. A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 33 (2008) 465-472
21. Grcevich S.J., Findling R.L., Rowane W.A., Friedman L., and Schulz S.C. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J. Child Adolesc. Psychopharmacol. 6 (1996) 251-257
22. Hall R.A., Massicotte G., Kessler M., Baudry M., and Lynch G. Thiocyanate equally increases affinity for two DL-alpha-amino-3-hydroxy-5-methylisoxazolepropionic acid (AMPA) receptor states. Mol. Pharmacol. 43 (1993) 459-464
23. Insel T.R., Miller L.P., and Gelhard R.E. The ontogeny of excitatory amino acid receptors in rat forebrain-I. N-methyl-d-aspartate and quisqualate receptors. Neuroscience 35 (1990) 31-43
24. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
25. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305 (2003) 625-631
26. Konradsson A., Marcus M.M., Hertel P., Svensson T.H., and Jardemark K.E. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 60 (2006) 102-108
27. 3 dopamine receptors. Cell. Mol. Neurobiol. 14 (1994) 185-191
28. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can. J. Psychiatry 43 (1998) 596-604
29. McCoy L., Cox C., and Richfield E.K. Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain. Eur. J. Pharmacol. 318 (1996) 41-45
30. McCoy L., Cox C., and Richfield E.K. Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression. Synapse 28 (1998) 195-207
31. McCracken J.T., McGough J., Shah B., Cronin P., Hong D., Aman M.G., Arnold L.E., Lindsay R., Nash P., Hollway J., McDougle C.J., Posey D., Swiezy N., Kohn A., Scahill L., Martin A., Koenig K., Volkmar F., Carroll D., Lancor A., Tierney E., Ghuman J., Gonzalez N.M., Grados M., Vitiello B., Ritz L., Davies M., Robinson J., McMahon D., and Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. 347 (2002) 314-321
32. Meshul C.K., Bunker G.L., Mason J.N., Allen C., and Janowsky A. Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J. Neurochem. 67 (1996) 1965-1973
33. Miller M.W. Development of projection and local circuit neurons in neocortex. In: Peters A., and Jones E.G. (Eds). Cerebral Cortex, Development and Maturation of Cerebral Cortex vol. 7 (1988), Plenum Press, New York 133-175
34. Moran-Gates T., Grady C., Park Y.S., Baldessarini R.J., and Tarazi F.I. Effects of risperidone on dopamine receptor subtypes in developing rat brain. Eur. Neuropsychopharmacol. 17 (2007) 448-455
35. 3H]alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid binding sites. J. Neurochem. 54 (1990) 686-695
36. Ninan I., Jardemark K.E., and Wang R.Y. Differential effects of atypical and typical antipsychotic drugs on N-methyl-d-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48 (2003) 66-79
37. Olsen C.K., Kreilgaard M., and Didriksen M. Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. Pharmacol. Biochem. Behav. 84 (2006) 259-265
38. Ozawa S., Kamiya H., and Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54 (1998) 581-618
39. Perry R., Pataki C., Munoz-Silva D.M., Armenteros J., and Silva R.R. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc. Psychopharmacol. 7 (1997) 167-179
40. 3H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc. Natl. Acad. Sci. U. S. .A. 84 (1987) 7744-7748
41. Schmidt W.J., and Bubser M. Anticataleptic effects of the N-methyl-d-aspartate antagonist MK-801 in rats. Pharmacol. Biochem. Behav. 32 (1989) 621-623
42. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 (1996) 57-73
43. Short K.R., and Tabakoff B. Chronic barbiturate treatment increases NMDA receptors but decreases kainate receptors in mouse cortex. Eur. J. Pharmacol. 230 (1993) 111-114
44. Spurney C.F., Baca S.M., Murray A.M., Jaskiw G.E., Kleinmann J.E., and Hyde T.M. Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse 34 (1999) 266-276
45. Tarazi F.I., Florijn W.J., and Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 128 (1996) 371-379
46. Tarazi F.I., Campbell A., Yeghiayan S.K., and Baldessarini R.J. Localization of glutamate receptor subtypes in caudate-putamen and nucleus accumbens septi: Comparison of NMDA, AMPA and kainate receptors. Synapse 30 (1998) 227-235
47. Tarazi F.I., Zhang K., and Baldessarini R.J. Effects of nigrostriatal dopamine denervation on ionotropic glutamate receptors in rat caudate-putamen. Brain Res. 881 (2000) 69-72
48. Tarazi F.I., Zhang K., and Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 297 (2001) 711-717
49. Tarazi F.I., Zhang K., and Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology 161 (2002) 263-270
50. Tarazi F.I., Baldessarini R.J., Kula N.S., and Zhang K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 306 (2003) 1145-1151
51. Tarsy D., Baldessarini R.J., and Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16 (2002) 23-45
52. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Ann. Rev. J. Pharmacol. Toxicol. 42 (2002) 165-179
53. Wullner U., Testa C.M., Catania M.V., Young A.B., and Penney J.B. Glutamate receptors in striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Res. 645 (1994) 98-102
54. Yoshida Y., Ono T., Kizu A., Fukushima R., and Miyagishi T. Striatal N-methyl-d-aspartate receptors in haloperidol-induced catalepsy. Eur. J. Pharmacol. 203 (1991) 173-180